| 1 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017,67(1):7-30.
|
| 2 |
Torre LA, Siegel RL, Jemal A. Lung cancer statistics[J]. Adv Exp Med Biol, 2016,893:1-19.
|
| 3 |
Lim E, Tay A, Von Der Thusen J, et al. Clinical results of microfluidic antibody-independent peripheral blood circulating tumor cell capture for thediagnosis of lung cancer[J]. J Thorac Cardiovasc Surg, 2013, 147(6):1936-1938.
|
| 4 |
Sawabata N. Prognosis of lung cancer patients in Japan according to data from the Japanese Joint Committee of Lung Cancer Registry[J]. Respir Investig, 2014,52(6):317-321.
|
| 5 |
Cho WC. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer[J]. Biomed Pharmacother, 2007,61(9): 515-519.
|
| 6 |
McGregor HC, Short MA, McWilliams A, et al. Real-time endoscopic Raman spcetroscopy for in vivo early lung cancer detection[J]. Biophotonics, 2017,10(1):98-100.
|
| 7 |
Kumar N, Shahjaman M, Mollah MNH, et al. Serum and plasma metabolomic biomarkers for lung cancer[J]. Bioinformation, 2017,13(6):202-208.
|
| 8 |
Liu L, Teng J, Zhang L，et al. The Combination of the tumor markers suggests the histological diagnosis of lung cancer[J]. Biomed Res Int, 2017,2017:2013989.
|
| 9 |
Wang W, Xu X, Tian B, et al. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer[J]. Clin Chim Acta, 2017,470:51-55.
|
| 10 |
Cho JY, Sung HJ. Proteomic approaches in lung cancer biomarker development[J]. Expert Rev Proteomics, 2009,6(1):27-42.
|
| 11 |
Takeuchi A, Oguri T, Sone K, et al. Predictive and prognostic value of CYFRA 21-1 for advanced non-small cell lung cancer treated with EGFR-TKIs[J]. Anticancer Res, 2017,37(10):5771-5776.
|
| 12 |
Zhang S, Zhao YF, Zhang MZ, et al. The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma[J]. Clin Respir J, 2017,11(4):481-488.
|
| 13 |
Dong HM, Le YQ, Wang YH, et al. Extracellular heat shock protein 90α mediates HDM-induced bronchial epithelial barrier dysfunction by activating RhoA/MLC signaling[J]. Respir Res, 2017,18(1):111.
|
| 14 |
Shi Y, Liu X, Lou J, et al. Plasma levels of heat shock protein 90 alpha associated with lung cancer development and treatment responses[J]. Clin Cancer Res, 2014,20(23):6016-6022.
|
| 15 |
Kobayashi M, Nagashio R, Ryuge S, et al. Acquisition of useful sero-diagnostic autoantibodies using the same patients′sera and tumor tissues[J]. Biomed Res, 2014,35(2):133-143.
|
| 16 |
Macdonald IK, Parsy-Kowalska CB, Chapman CJ. Autoantibodies: opportunities for early cancer detection[J]. Trends Cancer, 2017, 3(3):198-213.
|
| 17 |
Broodman I, Lindemans J, van Sten J, et al. Serum protein markers for the early detection of lung cancer: a focus on autoantibodies[J]. J Proteome Res, 2017,16(1):3-13.
|
| 18 |
Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure[J]. Thorax, 2008,63(3):228-233.
|
| 19 |
Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer[J].Ann Oncol, 2011,22(2): 383-389.
|
| 20 |
Chapman CJ, Healey GF, Murray A, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays[J]. Tumour Biol, 2012,33(5):1319-1326.
|
| 21 |
Jett JR, Peek LJ, Fredericks L, et al. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice[J]. Lung Cancer, 2014,83(1):51-55.
|
| 22 |
Sullivan FM, Farmer E, Mair FS, et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial[J]. BMC Cancer, 2017,17(1):187.
|
| 23 |
Massion PP, Healey GF, Peek LJ，et al. Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer[J]. J Thorac Oncol, 2017,12(3):578-584.
|
| 24 |
Jia S, Zhang R, Li Z，et al. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer[J]. Oncotarget, 2017,8(33):55632-55645.
|
| 25 |
Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer[J]. Oncotarget, 2016,7(30):48832-48841.
|
| 26 |
Li M, Diehl F, Dressman D, et al. BEAMing up for detection and quantifcation of rare sequence variants[J]. Nat Methods, 2006,3(2): 95-97.
|
| 27 |
Reinert T, Schøler LV, Thomsen R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery[J]. Gut, 2016,65(4):625-634.
|
| 28 |
Chen KZ, Lou F, Yang F, et al. Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing[J]. Sci Rep, 2016,6:31985.
|
| 29 |
Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNAwith broad patient coverage[J]. Nat Med, 2014,20(5):548-554.
|
| 30 |
Mishra PJ. MicroRNAs as promising biomarkers in cancer diagnostics[J]. Biomark Res, 2014,22(2):19.
|
| 31 |
Świtlik WZ, Szemraj J. Circulating miRNAs as non-invasive biomarkers for non-small cell lung cancer diagnosis, prognosis and prediction of treatment response[J]. Postepy Hig Med Dosw (Online), 2017,71:649-662.
|
| 32 |
Geng Q, Fan T, Zhang B et al. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer[J]. Respir Res, 2014,25(15):149.
|
| 33 |
Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating microRNA expression profiles in early stage nonsmall cell lung cancer[J]. Int J Cancer, 2012,130(6):1378-1386.
|
| 34 |
Foss KM, Sima C, Ugolini D, et al. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer[J]. J Thorac Oncol, 2011,6(3):482-488.
|
| 35 |
Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers[J]. BMC Cancer, 2011,24(11):374.
|
| 36 |
Carter L, Rothwell DG, Mesquita B,et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer[J]. Nat Med, 2017,23(1):114-119.
|
| 37 |
Hofman V, Bonnetaud C, llie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker[J]. Clin Cancer Res, 2011,17(4):827-835.
|
| 38 |
Sleijfer S, Gratama JW, Sieuwei′ts AM，et al．Circulating tumor cell detection on its way to routine diagnostic implementation[J]. Eur J Cancer, 2007,43(18):2645-2650．
|
| 39 |
He W, Wang H, Hartmann LC, et al. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry[J]. Proc Nat Acad Sci U S A, 2007,104(28):11760-11765.
|
| 40 |
Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer[J]. Clin Cancer Res, 2009, 15(22):6980-6986.
|
| 41 |
Carlsson A, Nair VS, Luttgen MS, et al. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer[J]. J Thorac Oncol, 2014,9(8):1111-1119．
|
| 42 |
Ilie M, Hofman V, Long-Mira E，et al. ″Sentinel″ circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One, 2014,9(10):e111597.
|